Drugmaker Pfizer Inc said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany's BioNTech SE , and provided a timeline that makes its ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

Pfizer Inc. remains attractive with strong fundamentals, cost control, an expanding market, and new drugs. Click here to read ...

Pfizer (PFE) stock is in focus as a Phase 3 trial for its Tukysa cancer drug as a first-line maintenance option in ...

Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial –NEW HAVEN, Conn., ...

Pfizer Inc "didn't conspire with anyone" to delay release of efficacy results for the COVID-19 vaccine it developed with German partner BioNTech SE until after the U.S. presidential election, Chief ...

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.

“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful ...

Pfizer and the rest of the biopharmaceutical industry have faced significant uncertainty. This uncertainty is due to the ...

Sen. Ruben Gallego (D-Ariz.) is raising concerns over the lack of details given about President Trump’s “most favored nation” ...